| Company Name: | Alnylam Pharmaceuticals, Inc. | | Ticker Symbol: | ALNY | | | WWW Address: | www.alnylam.com |
| CEO: | Dr. John M. Maraganore,PhD | | No. of Employees: | 115 |
| Common Issue Type: | CS | | Business Description: | Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 30.25 |  0.26 | 29.7 | 33.0 | 29.9 | 30.38 | 29.49 | 663645 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 1,880.7 | 62.2 | 1.29 | -2.11 | 0.00 | 0.0 | 0.0 | 31.79 - 11.20 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 30.36 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 1,880.7 | mil |
| Latest Shares Outstanding | 62.2 | mil |
| Earnings pS (EPS) | -2.11 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 517,248 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 53.6 | mil |
| Float as % of Shares Outstanding | 86.2 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 62.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 135.30 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | -97.8 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.2 | % |
| Return on Assets (ROA) | -22.0 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -33.3 | % |
| Current Ratio | 4.8 | |
| Leverage Ratio (Assets/Equity) | 1.5 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 3.06 | $ |
| Cash pS | 1.57 | $ |
| Book-Value pS | 5.01 | $ |
| Tangible Book-Value pS | 5.01 | $ |
| Cash Flow pS | -1.52 | $ |
| Free Cash Flow pS | -1.55 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 6.06 | |
| Price/Tangible Book Ratio | 6.06 | |
| Price/Cash Flow | -19.9 | |
| Price/Free Cash Flow | -19.6 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -1.8 | 99 | 4,620 | 16,742 |
| 4 Weeks | 31.79 | 26.57 | 27.44 | 10.6 | 113 | 4,158 | 74,842 |
| 13 Weeks | 31.79 | 21.60 | 25.00 | 21.4 | 116 | 4,002 | 248,142 |
| 26 Weeks | 31.79 | 17.31 | 18.54 | 63.8 | 141 | 4,726 | 581,276 |
| 52 Weeks | 31.79 | 11.20 | 11.58 | 162.2 | 215 | 4,485 | 1,112,301 |
| YTD | 31.79 | 18.61 | - | 66.4 | 145 | 4,937 | 557,891 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 30.55 | 30.34 | 26.23 | 23.09 | 21.64 | 1.29 | 1.94 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -3.04 | 9.0 | -12.96 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -18.58 | NA | -26.26 |
| R&D | -4.31 | NA | -6.92 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -9.4 | -9.4 | -19.4 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.10 | 0.10 | -0.75 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 26.82 |
| Current Ratio | 2.6 |
| Quick Ratio (Acid Test) | 2.5 |
| Liquidity Ratio (Cash) | 2.54 |
| Receivables Turnover | 84.9 |
| Average Collection Period | 4 |
| Working Capital/Equity | 57.5 |
| Working Capital pS | 1.47 |
| Cash-Flow pS | -1.85 |
| Free Cash-Flow pS | -2.36 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 5.94 |
| Financial Leverage Ratio (Assets/Equity) | 2.1 |
| Debt Ratio | 53.4 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 78.4 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 10.32 |
| Tobin's Q Ratio | 6.56 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -29.76 |
| Enterprise Value (EV)/Free Cash Flow | -14.77 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 6.06 |
| Price/Book Ratio - LTM | 6.06 |
| Price/Cash Flow Ratio | -19.9 |
| Price/Free Cash Flow Ratio - LTM | -19.6 |
| Price/Sales Ratio | 29.14 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.92 |
| Tangible Book Value pS - LTM | 5.01 |
| Book Value pS - LTM | 5.01 |
| Capital Invested pS | 2.16 |
| Cash pS - LTM | 1.57 |
| Cash Flow pS - LTM | -1.52 |
| Free Cash Flow pS - LTM | -1.55 |
| Earnings pS (EPS) | -2.11 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -185.77 |
| Free Cash Flow Margin 5YEAR AVG | -82.28 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | -63.0 |
| Equity Productivity | 0.50 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.50 |
| Return on Capital Invested (ROCI) | -79.1 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -35.6 |
| Assets Productivity | 0.20 |
| Return on Assets (ROA) | -36.9 |
| Return on Assets (ROA) - 5YEAR AVRG. | -14.1 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | -97.8 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -69.2 |
| Effective Tax Rate | 8.4 |
| Effective Tax Rate - 5YEAR AVRG. | 0.7 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 1 |
| Revenue per Employee | 517,248 |
| Net Income per Employee | -821,814 |
| Average Collection Period | 1 |
| Receivables Turnover | 84.9 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 6.62 |
| Assets/Revenue | 5.00 |
| Net Working Capital Turnover | 0.87 |
| Fixed Assets Turnover | 0.41 |
| Total Assets Turnover | 0.2 |
| Revenue per $ Cash | 1.30 |
| Revenue per $ Plant | 3.37 |
| Revenue per $ Common Equity | 0.50 |
| Revenue per $ Capital Invested | 0.50 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 66.9 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 42.1 |
| Research & Devlopment (R&D) as % of Revenue | 129.7 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 129.7 |
|
|  
|
| |
 |  |
